A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19

Severe coronavirus disease 2019 (COVID-19) is characterised by pneumonia with excessive systemic inflammation, referred to as a “cytokine storm” [1–3]. Dexamethasone treatment decreases mortality in patients with COVID-19 receiving respiratory support and is standard of care for severe COVID-19 [4, 5]. However, pulmonary inflammation, which drives COVID-19 morbidity and mortality [3], can persist despite corticosteroid use [6, 7]. Janus kinase (JAK) inhibition blocks signalling by many cytokines in diverse cell types, offering broad immunomodulation [8]. The oral JAK-1/2 inhibitor baricitinib combined with the antiviral remdesivir shows clinical efficacy in patients with severe COVID-19 [9]. Direct delivery of JAK inhibition to the lung via inhalation could overcome corticosteroid-resistant pulmonary inflammation [10], offering the potential for improved responses while minimising risk of excessive systemic immunosuppression. The novel inhaled pan-JAK inhibitor nezulcitinib (TD-0903) was designed to target all JAK isoforms (JAK1, JAK2, JAK3, TYK2; −log inhibition constant ≥9.2) and optimise delivery to the lungs while limiting systemic exposure (R. Sana and co-workers; unpublished results: abstract submitted to ERS International Congress, 2021). We report results from the completed part 1 of a 2-part phase 2 trial (NCT04402866) in hospitalised patients with severe COVID-19. The inhaled lung-selective pan-JAK inhibitor nezulcitinib appears generally well tolerated in hospitalised patients with severe #COVID-19, with trends for improved oxygenation and clinical status, shortened hospitalisation, and fewer deaths versus placebo https://bit.ly/35Xs1Rf

[1]  R. Webby,et al.  Synergism of TNF-α and IFN-γ Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes , 2020, Cell.

[2]  W. Lim,et al.  Dexamethasone in Hospitalized Patients with Covid-19 , 2021 .

[3]  Cameron R. Wolfe,et al.  Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 , 2020, The New England journal of medicine.

[4]  J. L. Rodríguez-García,et al.  Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study , 2020, Rheumatology.

[5]  R. Higgs,et al.  Characterization of the cytokine storm reflects hyperinflammatory endothelial dysfunction in COVID-19 , 2020, Journal of Allergy and Clinical Immunology.

[6]  Sharon J Peacock,et al.  Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. , 2020, JAMA.

[7]  N. McElvaney,et al.  Characterization of the Inflammatory Response to Severe COVID-19 Illness , 2020, American journal of respiratory and critical care medicine.

[8]  L. Dodd,et al.  Remdesivir for the Treatment of Covid-19 — Final Report , 2020, The New England journal of medicine.

[9]  D. Schwartz,et al.  JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects , 2017, Drugs.

[10]  Dave Singh,et al.  Anti-inflammatory potential of PI3Kδ and JAK inhibitors in asthma patients , 2016, Respiratory Research.

[11]  S. Keslacy,et al.  Cytokines induce an early steroid resistance in airway smooth muscle cells: novel role of interferon regulatory factor-1. , 2008, American journal of respiratory cell and molecular biology.